These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
    Author: Köse HC, Yalçındağ N.
    Journal: Ocul Immunol Inflamm; 2022 Jan 02; 30(1):203-207. PubMed ID: 32779960.
    Abstract:
    PURPOSE: To evaluate the clinical course of patients with Behçet uveitis after discontinuation of infliximab (IFX) therapy. METHODS: Medical records of eight patients who discontinued treatment between 2010 and 2018 were retrospectively analyzed. The main outcome measures were frequency of uveitis attacks per year, best-corrected visual acuity (BCVA), aqueous flare, foveal thickness and fluorescein angiography (FA) scores before initiation, during treatment and after 6, 12, and 24 months of cessation of the IFX therapy. RESULTS: The mean follow-up after withdrawal of infusions was 38.6 ± 20.4 (12-90) months. Frequency of uveitis attacks, BCVA, aqueous flare, foveal thickness and FA scores were improved significantly after treatment (p < .05). In terms of these parameters, there was no significant difference between the periods of during treatment and after 6, 12, and 24 months of cessation of the IFX therapy. CONCLUSION: IFX therapy might be discontinued safely with an effective inflammation control in patients with Behçet uveitis.
    [Abstract] [Full Text] [Related] [New Search]